3464-82-2

Usage

Also known as

6-Methyltetrahydropyridoindol-1-one

Type of compound

Derivative of Pyridoindole

Usage

Intermediate in the synthesis of various drugs in the pharmaceutical industry

Therapeutic potential

Neurological disorders, anti-cancer properties

Physical form

Pale yellow solid

Melting point

126-128°C

Molecular weight

211.25 g/mol

Importance

Diverse potential applications in medicine and drug development.

Upstream product

• 3464-81-1 2,3-Dioxo-piperidin-p-tolylhydrazon-⁽³⁾ 

Downstream Products

• 104510-00-1 3-(2-amino-ethyl)-5-methyl-indole-2-carboxylic acid 
• 1054620-76-6 (3aS,4S,6R,6aR)-6-(6-{2-[1-(2,5-Dimethyl-benzyl)-5-methyl-1H-indol-3-yl]-ethylamino}-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid cyclopropylamide 
• 163838-04-8 UP 202-56 
• 174727-68-5 2-[1-(2,5-Dimethyl-benzyl)-5-methyl-1H-indol-3-yl]-ethylamine 
• 1010-95-3 5-methyltryptamine hydrochloride 

Relevant academic research and scientific papers

N6-Substituted Adenosine Receptor Agonists. Synthesis and Pharmacological Activity as Potent Antinociceptive Agents

Novel N6-(indol-3-yl)alkyl derivatives of adenosine were synthesized.The adenosine receptor affinity and the antinociceptive activity of these compounds were assessed in binding studies and the phenylbenzoquinone-induced writhing test.Most of these analogues exhibited a potent analgesic activity without side effects.Among them, compound 3c (UP 202-32) bound to A1 (Ki = 110 nM) and A2 (Ki = 350 nM) adenosine receptors in a specific manner since it did not interact with many other receptors, especially opioid binding sites.The antinociceptive activity in the phenylbenzoquinone assay (ED50 = 3.3 mg/kg po) was antagonized by 8-cyclopentyltheophylline, suggesting that an adenosinergic mechanism underlies the analgesic activity observed with this compound.The data obtained with these new N6-substituted adenosine receptor agonists emphasize the interest of such compounds in the treatment of pain.